Identification of the binding site of Brucella VirB8 interaction inhibitors

Chemistry and Biology

Volumn 19, Issue 8, 2012, Pages 1041-1048

  Smith, Mark A ^a   Coinon, Mathieu ^a   Paschos, Athanasios ^b   Jolicoeur, Benoit ^a   Lavallée, Pierre ^a   Sygusch, Jurgen ^a   Baron, Christian ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

B8I 1; B8I 2; BACTERIAL PROTEIN; PROTEIN INHIBITOR; PROTEIN VIRB8; UM 0125823; UM 0125824; UM 0125848; UM 0125850; UM 1125848; UNCLASSIFIED DRUG; VIRULENCE FACTOR;

ARTICLE; BACTERIAL VIRULENCE; BINDING AFFINITY; BRUCELLA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIMERIZATION; DRUG BINDING SITE; DRUG POTENCY; DRUG PROTEIN BINDING; HOST PATHOGEN INTERACTION; MOLECULAR DOCKING; NONHUMAN; PATHOGENICITY; PROTEIN ASSEMBLY; SITE DIRECTED MUTAGENESIS; STRUCTURE ACTIVITY RELATION; SURVIVAL; TYPE IV SECRETION SYSTEM; X RAY CRYSTALLOGRAPHY;

AMINO ACID SUBSTITUTION; BACTERIAL PROTEINS; BINDING SITES; BRUCELLA; COMPUTER SIMULATION; CRYSTALLOGRAPHY, X-RAY; DIMERIZATION; HIGH-THROUGHPUT SCREENING ASSAYS; KINETICS; PROTEIN STRUCTURE, TERTIARY; STRUCTURE-ACTIVITY RELATIONSHIP; VIRULENCE FACTORS;

BACTERIA (MICROORGANISMS); BRUCELLA;

EID: 84865451331     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chembiol.2012.07.007     Document Type: Article

References (29)

1. P.D. Adams, R.W. Grosse-Kunstleve, L.W. Hung, T.R. Ioerger, A.J. McCoy, N.W. Moriarty, R.J. Read, J.C. Sacchettini, N.K. Sauter, and T.C. Terwilliger PHENIX: building new software for automated crystallographic structure determination Acta Crystallogr. D Biol. Crystallogr. 58 2002 1948 1954 (Pubitemid 35337293)
2. L.E. Alksne, and S.J. Projan Bacterial virulence as a target for antimicrobial chemotherapy Curr. Opin. Biotechnol. 11 2000 625 636
3. C.E. Alvarez-Martinez, and P.J. Christie Biological diversity of prokaryotic type IV secretion systems Microbiol. Mol. Biol. Rev. 73 2009 775 808
4. L. Andrieux, G. Bourg, A. Pirone, D. O'Callaghan, and G. Patey A single amino acid change in the transmembrane domain of the VirB8 protein affects dimerization, interaction with VirB10 and Brucella suis virulence FEBS Lett. 585 2011 2431 2436
5. S. Bailey, D. Ward, R. Middleton, J.G. Grossmann, and P.C. Zambryski Agrobacterium tumefaciens VirB8 structure reveals potential protein-protein interaction sites Proc. Natl. Acad. Sci. USA 103 2006 2582 2587
6. C. Baron From bioremediation to biowarfare: on the impact and mechanism of type IV secretion systems FEMS Microbiol. Lett. 253 2005 163 170 (Pubitemid 41674512)
7. C. Baron VirB8: a conserved type IV secretion system assembly factor and drug target Biochem. Cell Biol. 84 2006 890 899 (Pubitemid 46450689)
8. C. Baron Antivirulence drugs to target bacterial secretion systems Curr. Opin. Microbiol. 13 2010 100 105
9. T.H. Bayburt, and S.G. Sligar Membrane protein assembly into nanodiscs FEBS Lett. 584 2010 1721 1727
10. G. Bourg, R. Sube, D. O'Callaghan, and G. Patey Interactions between Brucella suis VirB8 and its homolog TraJ from the plasmid pSB102 underline the dynamic nature of type IV secretion systems J. Bacteriol. 191 2009 2985 2992
11. A.E. Clatworthy, E. Pierson, and D.T. Hung Targeting virulence: a new paradigm for antimicrobial therapy Nat. Chem. Biol. 3 2007 541 548 (Pubitemid 47294400)
12. G.R. Cornelis The type III secretion injectisome, a complex nanomachine for intracellular 'toxin' delivery Biol. Chem. 391 2010 745 751
13. K. Dalal, and F. Duong Reconstitution of the SecY translocon in nanodiscs Methods Mol. Biol. 619 2010 145 156
14. P. Emsley, and K. Cowtan Coot: model-building tools for molecular graphics Acta Crystallogr. D Biol. Crystallogr. 60 2004 2126 2132 (Pubitemid 41742764)
15. R. Fronzes, P.J. Christie, and G. Waksman The structural biology of type IV secretion systems Nat. Rev. Microbiol. 7 2009 703 714
16. G. Karimova, N. Dautin, and D. Ladant Interaction network among Escherichia coli membrane proteins involved in cell division as revealed by bacterial two-hybrid analysis J. Bacteriol. 187 2005 2233 2243 (Pubitemid 40389120)
17. A.M. Kauppi, R. Nordfelth, H. Uvell, H. Wolf-Watz, and M. Elofsson Targeting bacterial virulence: inhibitors of type III secretion in Yersinia Chem. Biol. 10 2003 241 249 (Pubitemid 36380281)
18. P. Keyser, M. Elofsson, S. Rosell, and H. Wolf-Watz Virulence blockers as alternatives to antibiotics: type III secretion inhibitors against Gram-negative bacteria J. Intern. Med. 264 2008 17 29 (Pubitemid 351813482)
19. T.F. Moraes, T. Spreter, and N.C. Strynadka Piecing together the type III injectisome of bacterial pathogens Curr. Opin. Struct. Biol. 18 2008 258 266
20. G.M. Morris, D.S. Goodsell, R.S. Halliday, R. Huey, W.E. Hart, R.K. Belew, and A.J. Olson Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function J. Comput. Chem. 19 1998 1639 1662 (Pubitemid 128590223)
21. G.M. Morris, R. Huey, and A.J. Olson Using AutoDock for ligand-receptor docking Curr. Protoc Bioinformatics 2008 Chapter 8, Unit 8.14
22. S. Muschiol, L. Bailey, A. Gylfe, C. Sundin, K. Hultenby, S. Bergström, M. Elofsson, H. Wolf-Watz, S. Normark, and B. Henriques-Normark A small-molecule inhibitor of type III secretion inhibits different stages of the infectious cycle of Chlamydia trachomatis Proc. Natl. Acad. Sci. USA 103 2006 14566 14571 (Pubitemid 44484790)
23. A. Negrea, E. Bjur, S.E. Ygberg, M. Elofsson, H. Wolf-Watz, and M. Rhen Salicylidene acylhydrazides that affect type III protein secretion in Salmonella enterica serovar typhimurium Antimicrob. Agents Chemother. 51 2007 2867 2876 (Pubitemid 47206224)
24. A. Paschos, G. Patey, D. Sivanesan, C. Gao, R. Bayliss, G. Waksman, D. O'callaghan, and C. Baron Dimerization and interactions of Brucella suis VirB8 with VirB4 and VirB10 are required for its biological activity Proc. Natl. Acad. Sci. USA 103 2006 7252 7257 (Pubitemid 43727819)
25. A. Paschos, A. den Hartigh, M.A. Smith, V.L. Atluri, D. Sivanesan, R.M. Tsolis, and C. Baron An in vivo high-throughput screening approach targeting the type IV secretion system component VirB8 identified inhibitors of Brucella abortus 2308 proliferation Infect. Immun. 79 2011 1033 1043
26. D. Sivanesan, and C. Baron The dimer interface of Agrobacterium tumefaciens VirB8 is important for type IV secretion system function, stability, and association of VirB2 with the core complex J. Bacteriol. 193 2011 2097 2106
27. L. Terradot, R. Bayliss, C. Oomen, G. Leonard, C. Baron, and G. Waksman Structures of two core subunits of the bacterial type IV secretion system, VirB8 from Brucella suis and ComB10 from Helicobacter pylori Proc. Natl. Acad. Sci. USA 102 2005 4596 4601 (Pubitemid 40397157)
28. J.J. Tree, D. Wang, C. McInally, A. Mahajan, A. Layton, I. Houghton, M. Elofsson, M.P. Stevens, D.L. Gally, and A.J. Roe Characterization of the effects of salicylidene acylhydrazide compounds on type III secretion in Escherichia coli O157:H7 Infect. Immun. 77 2009 4209 4220
29. D. Wang, C.E. Zetterström, M. Gabrielsen, K.S. Beckham, J.J. Tree, S.E. Macdonald, O. Byron, T.J. Mitchell, D.L. Gally, and P. Herzyk Identification of bacterial target proteins for the salicylidene acylhydrazide class of virulence-blocking compounds J. Biol. Chem. 286 2011 29922 29931